Instytut Biologii Medycznej PAN

Labs > Cellular Signaling > Currently ongoing projects

Currently ongoing projects

Neuromedin U, new potential regulator of colorectal cancer metastasis mechanisms.
SONATA BIS, 2016-2020 Granted by National Science Centre (NCN);
Investigator – dr Patrycja Przygodzka

Colorectal cancer is the third most lethal invasive cancer in Poland. Therapy choice, metastasis and tumor recurrence are critical processes influencing the CRC treatment. The most successful therapeutic approach in colorectal cancer (CRC) is the resection of the tumor during the early stages of disease. However, even when diagnosed early, new putative CRC progression markers are still needed to help with prediction of clinically latent versus invasive tumors and qualify patients for more aggressive adjuvant therapy. CRC subtypes were identified but their ability to metastasis need to be further investigated. In the current project we propose that neuromedin U is involved in active regulation of colorectal cancer progression and may have a potential as a new marker of the process.

Analysis of NMU expression, signaling induction, release and extracellular abundance in CRC cells, tissues and surrounding cells, will shed more light on the potential function of this molecule as a regulator, potential target for therapy and the marker of the early stages of colorectal cancer metastatic process.


Preparation of optimal research model for project: "Non-canonical activity of ABCC4 protein in cancer"
MINIATURA 2. 2018-2019 Granted by National Science Center
Principal Investigator - Jakub Kryczka

For many years cancer multidrug resistance has been a huge challenge for both clinicist and scientists. Overcoming its effect, may increase patients survival rate. Cancer cells developed number of mechanisms, allowing them, both survival and progression in human organism as well as resistance to the anticancer therapy. Multidrug resistance proteins (MRP) belong to the superfamily of ABC (ATP binding cassette) proteins, active transporters with broad range of substrate spectrum. They are responsible for the transport of potentially harmful xenobiotics, including anticancer drugs, such as: doxorubicin, cisplatin, topotecan, vincristine, MTX or vinblastine. Even though, MRP are present in many cell types, thus far, they have been studied primarily in cancer cells. Recent data suggests, that function of MRP may be far more complex than thought previously, as members of ABC proteins may be involve in regulation of cell migration. This data are highly significant, as cancer cells might acquire high migratory phenotype during anticancer chemotherapy. Most recent data suggest that neoadjuvant  chemotherapy, despite decreased primary tumor volume may inflict higher metastasis leading to increased mortality. Understanding and overcoming its effect, may improve patients survival rate. In this project Squamous Cell Carcinoma cell lines SCC9, SCC15 and SCC25 as well as Colon Adenocarcinoma grade II cell line HT-29 serve as a research model. Our obtained data shows unexplained and yet undescribed correlation between cancer cell migration and MRP activity.

Labs > Cellular Signaling > Currently ongoing projects